Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 6, 2012, Pages 512-519

  Huang, Grace ^a   Coviello, Andrea ^a,b  

^a Department of Internal Medicine   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; dyslipidemia; insulin resistance; metabolic syndrome; obesity; polycystic ovary syndrome

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 2; DEEND1A GENE; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN RESISTANCE; LHCGR GENE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; REVIEW;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; DYSLIPIDEMIAS; FATTY LIVER; FEMALE; HUMANS; INFERTILITY, FEMALE; INSULIN RESISTANCE; MASS SCREENING; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; RISK FACTORS;

EID: 84869889537     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835a000e     Document Type: Review

References (76)

1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-2749.
2. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25:544-551.
3. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.
4. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003; 14:365-370.
5. Glintborg D, Mumm H, Ravn P, et al. Age associated differences in prevalence of individual rotterdam criteria and metabolic risk factors during reproductive age in 446 Caucasian women with polycystic ovary syndrome. Horm Metab Res 2012; In Press.
6. Brzozowska MM, Ostapowicz G, Weltman MD. An association between nonalcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24:243-247.
7. Zawadski, JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Boston, MA: Blackwell Scientific; 1992. pp. 377-384.
8. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
9. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91:4237-4245.
10. Polotsky AJ, Allshouse A, Crawford SL, et al. Relative Contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. J Clin Endocrinol Metab 2012; 97:E868-E877.
11. Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011; 7:219-231.
12. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005; 11:126-134.
13. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456-488.
14. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
15. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038-2049.
16. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59:141-154.
17. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12:324-332.
18. Tosi F, Negri C, Perrone F, et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2012; 97:1712-1719.
19. Kahal H, Atkin SL, Sathyapalan T. Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J Obes 2011; 2011:402052.
20. Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001; 7:405-410.
21. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005; 11:631-643.
22. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007; 3:103-111.
23. Chazenbalk G, Chen YH, Heneidi S, et al. Abnormal expression of genes involved in inflammation, lipid metabolism, and wnt signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab 2012; 97:E765-E770.
24. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33. 3 Nat Genet 2011; 43:55-59.
25. Goodarzi MO, Jones MR, Li X, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2012; 49:90-95.
26. Welt CK, Styrkarsdottir U, Ehrmann DA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab 2012; 97:E1342-E1347.
27. Lerchbaum E, Trummer O, Giuliani A, et al. Susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21, and 9q333 in a cohort of Caucasian women. Horm Metab Res 2011; 43:743-747.
28. Xu N, Kwon S, Abbott DH, et al. Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One 2011; 6:e27286.
29. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006; 91:1660-1666.
30. Xu N, Azziz R, Goodarzi MO. Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation. Fertil Steril 2010; 94:781-783; e1.
31. Centers for Disease Control and Prevention. Major cardiovascular disease (CVD) during 1997-1999 and major CVD hospital discharge rates in 1997 among women with diabetes-United States. MMWR Morb Mortal Wkly Rep 2001; 50:948-954.
32. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, et al. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007; 18:280-285.
33. Wild RA, Rizzo M, Clifton S, et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95:1073-1079.
34. Westerveld HE, Hoogendoorn M, de Jong AW, et al. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Ther 2008; 119:223-241.
35. Wild RA. Dyslipidemia in PCOS. Steroids 2012; 77:295-299.
36. Castelo-Branco C, Steinvarcel F, Osorio A, et al. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol Endocrinol 2010; 26:736-742.
37. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92:456-461.
38. Kazerooni T, Shojaei-Baghini A, Dehbashi S, et al. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, doubleblind, placebo-controlled study. Fertil Steril 2010; 94:2208-2213.
39. Raval AD, Hunter T, Stuckey B, et al. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 2011:CD008565.
40. Rashidi B, Abediasl J, Tehraninejad E, et al. Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial. J Investig Med 2011; 59: 912-916.
41. Rizzo M, Berneis K, Carmina E, et al. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol 2008; 198:28.
42. Vrbikova J, Cibula D, Dvoráková K, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:2942-2945.
43. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006; 86 (Suppl 1):S13-S14.
44. Lungu AO, Zadeh ES, Goodling A, et al. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2012; 97:563-567.
45. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48-53.
46. Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1929-1935.
47. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91:492-497.
48. Hurd WW, Abdel-Rahman MY, Ismail SA, et al. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril 2011; 96:1043-1047.
49. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010; 22:466-476.
50. Ziaee A, Oveisi S, Abedini A, et al. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. Acta Med Indones 2012; 44:16-22.
51. Yasmin E, Glanville J, Barth J, et al. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 156:67-71.
52. Liao L, Tian YJ, Zhao JJ, et al. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J (Engl) 2011; 124:714-718.
53. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011; 95:203-209.
54. Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012; 97:1492-1500.
55. De Leo V, Musacchio MC, Piomboni P, et al. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol 2011; 157:63-66.
56. Ghazeeri GS, Nassar AH, Younes Z, et al. Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstet Gynecol Scand 2012; 91:658-678.
57. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf) 2007; 66:373-379.
58. Glueck CJ, Dharashivkar S, Wang P, et al. Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 2005; 122:206-212.
59. Karabulut A, YaylaliGF, Demirlenk S, et al. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecol Endocrinol 2012; 28:111-114.
60. Lass N, Kleber M, Winkel K, et al. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011; 96:3533-3540.
61. Stamets K, Taylor DS, Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004; 81:630-637.
62. Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92:1966-1982.
63. Harrison CL, Lombard CB, Moran LJ, et al. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2011; 17:171-183.
64. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90:6364-6369.
65. Rector RS, Thyfault JP, Wei Y, et al. Nonalcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14:185-192.
66. Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1741-1747.
67. Economou F, Xyrafis X, Livadas S, et al. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009; 8:199-206.
68. Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25:212-220.
69. Gutierrez-Grobe Y, et al. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9:402-409.
70. Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-1609.
71. Lim CE, Wong WS. Current evidence of acupuncture on polycystic ovarian syndrome. Gynecol Endocrinol 2010; 26:473-478.
72. Raja-Khan N, Stener-Victorin E, Wu X, et al. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2011; 301:E1-E10.
73. Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011; 17:741-760.
74. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006; 185:227-239.
75. Schmidt J, Landin-Wilhelmsen K, Brä nnström M, et al. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96:3794-3803.
76. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24:302-312.